Doxycap - Doxycap is an semisynthetic tetracycline group's antibiotic of broad-spectrum. This medication has bacteriostatic action due to suppression of protein synthesis of pathogens. It active against aerobic gram-positive bacteria: Staphylococcus spp. (including strains producing penicillinase), Streptococcus spp. (including Streptococcus pneumoniae), Bacillus anthracis, Listeria monocytogenes; anaerobic bacteria: Clostridium spp.
Doxycap is also active against aerobic gram-negative bacteria: Neisseria gonorrhoeae, Escherichia coli, Shigella spp., Salmonella spp., Enterobacter spp., Klebsiella spp., Bordetella pertussis, as well as against Rickettsia spp., Treponema spp., Mycoplasma spp. and Chlamydia spp.
Pseudomonas aeruginosa, Proteus spp., Serratia spp., most strains of Bacteroides fragilis are resistant to doxycycline.
Doxycap is an antibiotic. It is used to treat certain bacterial infections of the nose, ears, lung, skin, bone, stomach and bladder. Doxycap is also used to treat dental infections, sexually-transmitted diseases (STD) such as syphilis or gonorrhoea. It may also be used to treat and prevent malaria. Doxycap belongs to a group of antibiotics called the tetracyclines.
Indications: bacterial infections
Doxycap is a member of the tetracycline antibiotics group and is commonly used to treat a variety of infections. Doxycap is a semi-synthetic tetracycline invented and clinically developed in the early 1960s by Pfizer Inc. and marketed under the brand name Vibramycin. Vibramycin received U.S. Food and Drug Administration (FDA) approval in 1967, becoming Pfizer's first once-a-day broad-spectrum antibiotic. Other brand names include Monodox, Microdox, Periostat, Vibra-Tabs, Oracea, Doryx, Vibrox, Adoxa, Doxyhexal, Doxylin, and Atridox (topical Doxycap hyclate for periodontitis).
Indications: Respiratory, genito-urinary, dental, ophthalmic, ENT and gynaecological infections.